A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) (EXHALE-3)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma
Sponsor: Areteia Therapeutics
Terminated
Program stopped due to the benefit risk profile no longer supports further development in the intended patient population.
Other terminated trials from Areteia Therapeutics
More terminations from Areteia Therapeutics
Listed as NCT05813288, this PHASE3 trial focuses on Asthma and Asthma; Eosinophilic and remains terminated or withdrawn. Sponsored by Areteia Therapeutics, it has been updated 16 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
▶ Show 11 earlier versions
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Mar 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Areteia Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .